Clinical Trials Browser

Phase 1 × Panobinostat × Dermatologic × Clear all

NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Phase 1 Completed

17 enrolled 12 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00962507 2013-02-15

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Phase 1 Completed

11 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT00412997 2012-11-27

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Phase 1 Completed

14 enrolled

DermatologicLymphoid

Neoplasms, Lymphoma, T-Cell, Cutaneous